What is the current valuation of the US antifungal treatment market?

The market valuation was $3760.0 Million in 2024. Read More

What is the projected market size for the US antifungal treatment market by 2035?

The projected valuation for 2035 is $5800.0 Million. Read More

What is the expected CAGR for the US antifungal treatment market during the forecast period 2025 - 2035?

The expected CAGR is 4.02% during the forecast period 2025 - 2035. Read More

Which drug class holds the largest market share in the US antifungal treatment market?

Azoles appear to hold the largest market share, with valuations ranging from $1500.0 Million to $2300.0 Million. Read More

What are the key routes of administration for antifungal treatments in the US market?

The primary routes of administration include Oral, Topical, and Parenteral, with Oral treatments valued between $1500.0 Million and $2400.0 Million. Read More

Which indication has the highest market valuation in the US antifungal treatment market?

Candidiasis has the highest market valuation, estimated between $1200.0 Million and $1800.0 Million. Read More

What pathogens are primarily targeted by antifungal treatments in the US market?

The primary pathogens include Candida, Aspergillus, and Cryptococcus, with Candida valued between $800.0 Million and $1200.0 Million. Read More

Who are the key players in the US antifungal treatment market?

Key players include Pfizer Inc, Bristol-Myers Squibb Company, Merck & Co Inc, and Gilead Sciences Inc. Read More

What is the market valuation for hospitals and clinics as end users of antifungal treatments?

Hospitals & Clinics had a market valuation ranging from $1500.0 Million to $2300.0 Million. Read More

What is the expected growth trend for the US antifungal treatment market in the coming years?

The market is likely to experience steady growth, with a projected increase to $5800.0 Million by 2035. Read More

US Antifungal Treatment Market

ID: MRFR/Pharma/14707-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

US Antifungal Treatment Market Research Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamine, Pyrimidines, Others), By Technology (Oral, Topical, Parenteral), By Indication (Dermatophytosis, Aspergillosis, Candidiasis, Invasive Candidiasis, Vulvovaginal Candidiasis, Mouth/Throat/Esophageal Candidiasis, Others), By Pathogen (Candida, Aspergillus, Cryptococcus, Coccidioides Immitis, Zygomycetes, Trichophyton, Others) and By End User (Hospitals & Clinics, Dermatology Clinics, Others) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Drug Class (USD Million)
  1. 4.1.1 Azoles
  2. 4.1.2 Echinocandins
  3. 4.1.3 Polyenes
  4. 4.1.4 Allylamine
  5. 4.1.5 Pyrimidines
  6. 4.1.6 Others
2. 4.2 Chemicals and Materials, BY Route of Administration (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Topical
  3. 4.2.3 Parenteral
3. 4.3 Chemicals and Materials, BY Indication (USD Million)
  1. 4.3.1 Dermatophytosis
  2. 4.3.2 Aspergillosis
  3. 4.3.3 Candidiasis
  4. 4.3.4 Invasive Candidiasis
  5. 4.3.5 Vulvovaginal Candidiasis
  6. 4.3.6 Mouth/Throat/Esophageal Candidiasis
  7. 4.3.7 Others
4. 4.4 Chemicals and Materials, BY Pathogen (USD Million)
  1. 4.4.1 Candida
  2. 4.4.2 Aspergillus
  3. 4.4.3 Cryptococcus
  4. 4.4.4 Coccidioides Immitis
  5. 4.4.5 Zygomycetes
  6. 4.4.6 Trichophyton
  7. 4.4.7 Others
5. 4.5 Chemicals and Materials, BY End User (USD Million)
  1. 4.5.1 Hospitals & Clinics
  2. 4.5.2 Dermatology Clinics
  3. 4.5.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb Company (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck & Co Inc (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Gilead Sciences Inc (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Astellas Pharma Inc (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis AG (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bayer AG (DE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 GlaxoSmithKline plc (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DRUG CLASS
3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY INDICATION
5. 6.5 US MARKET ANALYSIS BY PATHOGEN
6. 6.6 US MARKET ANALYSIS BY END USER
7. 6.7 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF CHEMICALS AND MATERIALS
10. 6.10 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
12. 6.12 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
13. 6.13 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 (% SHARE)
14. 6.14 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 TO 2035 (USD Million)
15. 6.15 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
16. 6.16 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
17. 6.17 CHEMICALS AND MATERIALS, BY INDICATION, 2024 (% SHARE)
18. 6.18 CHEMICALS AND MATERIALS, BY INDICATION, 2024 TO 2035 (USD Million)
19. 6.19 CHEMICALS AND MATERIALS, BY PATHOGEN, 2024 (% SHARE)
20. 6.20 CHEMICALS AND MATERIALS, BY PATHOGEN, 2024 TO 2035 (USD Million)
21. 6.21 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
22. 6.22 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY INDICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY PATHOGEN, 2025-2035 (USD Million)
  5. 7.2.5 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Drug Class (USD Million, 2025-2035)

Azoles
Echinocandins
Polyenes
Allylamine
Pyrimidines
Others

Chemicals and Materials By Route of Administration (USD Million, 2025-2035)

Oral
Topical
Parenteral

Chemicals and Materials By Indication (USD Million, 2025-2035)

Dermatophytosis
Aspergillosis
Candidiasis
Invasive Candidiasis
Vulvovaginal Candidiasis
Mouth/Throat/Esophageal Candidiasis
Others

Chemicals and Materials By Pathogen (USD Million, 2025-2035)

Candida
Aspergillus
Cryptococcus
Coccidioides Immitis
Zygomycetes
Trichophyton
Others

Chemicals and Materials By End User (USD Million, 2025-2035)

Hospitals & Clinics
Dermatology Clinics
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”